CTLA4 and neoplasm: We report here for the first time on signaling pathways downstream CTLA-4 in tumor and NK cells revealed by using Ipilimumab, the approved FDA anti-CTLA-4 mAb, in parallel studies with two novel human mAbs we isolated by using an efficient phage display selection strategy for mouse-human CTLA-4 cross-reactivity.